Rua Bioscience Limited — Director's Dealing 2023

Jul 18, 2023

==> picture [93 x 26] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

==> picture [419 x 495] intentionally omitted <==

----- Start of picture text ----- To NZX Limited; andName of listed issuer: Rua Bioscience Limited (Rua)Date this disclosure made: 19-Jul-23Date of last disclosure: 31-May-23Director or senior manager giving disclosureFull name(s): Hamish WhiteName of listed issuer: Rua Bioscience LimitedName of related body corporate (if applicable): N/APosition held in listed issuer: Former CFOSummary of acquisition or disposal of relevant interest (excluding specified derivatives)Class of affected quoted financial products: Ordinary sharesNature of the affected relevant interest(s): Legal and beneficial holderFor that relevant interest-Number held in class before acquisition or disposal: 80,895Number held in class after acquisition or disposal: 197,893Current registered holder(s): Hamish WhiteRegistered holder(s) once transfers are registered: Hamish WhiteSummary of acquisition or disposal of specified derivatives relevant interest (if applicable)Type of affected derivative: N/AClass of underlying financial products: N/ADetails of affected derivative-The notional value of the derivative (if any) or the notional amount of underlyingfinancial products (if any): N/AA statement as to whether the derivative is cash settled or physically settled: N/AMaturity date of the derivative (if any): N/AExpiry date of the derivative(if any): N/AThe price specified in the terms of the derivative (if any): N/AAny other details needed to understand how the amount of the consideration payableunder the derivative or the value of the derivative is affected by the value of theunderlying financial products: N/AFor that derivative,-Parties to the derivative: N/AIf the director or senior manager is not a party to the derivative, the nature of therelevant interest in the derivative: N/ADetails of transactions giving rise to acquisition or disposalTotal number of transactions to which notice relates: One----- End of picture text -----

Details of transactions requiring disclosure-

==> picture [419 x 607] intentionally omitted <==

----- Start of picture text ----- Date of transaction: 30-Jun-23Nature of transaction: Issue of ordinary sharesName of any other party or parties to the transaction (if known): Rua Bioscience Limted as issuerThe consideration, expressed in New Zealand dollars, paid or received for theacquisition or disposal. If the consideration was not in cash and cannot be readily byconverted into a cash value, describe the consideration: Nil - issued for no cash considerationNumber of financial products to which the transaction related: 116,998 ordinary sharesIf the issuer has a financial products trading policy that prohibits directors or seniormanagers from trading during any period without written clearance (a closed period)include the following details—Whether relevant interests were acquired or disposed of during a closed period: YesWhether prior written clearance was provided to allow the acquisition or disposal toproceed during the closed period: YesDate of the prior written clearance (if any): 30-Jun-23Summary of other relevant interests after acquisition or disposal:Class of quoted financial products: NilNature of relevant interest: NilFor that relevant interest,-Number held in class: N/ACurrent registered holder(s): N/AFor a derivative relevant interest,-Type of derivative: N/ADetails of derivative,-The notional value of the derivative (if any) or the notional amount of underlyingN/Afinancial products (if any):A statement as to whether the derivative is cash settled or physically settled: N/AMaturity date of the derivative (if any): N/AExpiry date of the derivative (if any): N/AThe price's specified terms (if any): N/AAny other details needed to understand how the amount of the consideration payableunder the derivative or the value of the derivative is affected by the value of the N/Aunderlying financial products:For that derivative relevant interest,- N/AParties to the derivative: N/AIf the director or senior manager is not a party to the derivative, the nature of the N/Arelevant interest in the derivative:CertificationI, certify that, to the best of my knowledge and belief, the information contained in thisdisclosure is correct and that I am duly authorised to make this disclosure by allpersons for whom it is made.Signature of director or officer: Hamish WhiteDate of signature:orSignature of person authorised to sign on behalf of director or officer:Date of signature:Name and title of authorised person:----- End of picture text -----